Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

Morimoto, Kenji; Yamada, Tadaaki; Kawachi, Hayato; Tamiya, Motohiro; Negi, Yoshiki; Goto, Yasuhiro; Nakao, Akira; Shiotsu, Shinsuke; Tanimura, Keiko; Takeda, Takayuki; Okada, Asuka; Harada, Taishi; Date, Koji; Chihara, Yusuke; Hasegawa, Isao; Tamiya, Nobuyo; Nishioka, Naoya; Katayama, Yuki; Iwasaku, Masahiro; Tokuda, Shinsaku; Kijima, Takashi; Takayama, Koichi

doi:10.1007/s11523-023-01012-1

Targ Oncol

2023

DOI: 10.1007/s11523-023-01012-1

|View full text |Cite

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

Kenji Morimoto,

Tadaaki Yamada,

Hayato Kawachi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy

Morimoto,

Hamashima,

Yamada

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundAdvances in anticancer drugs for lung cancer (LC) have improved the prognosis of LC. Chronic pulmonary aspergillosis (CPA) is a progressive and often exacerbating respiratory disease with a poor prognosis. To date, the prognosis of LC complicated by CPA has not been elucidated. This study investigated the clinical implications of concomitant CPA in patients with LC undergoing anticancer drug treatment.MethodsBetween January 2010 and May 2020, we consecutively enrolled patients with LC complicated with CPA at five different institutions in Japan. We analyzed patients with LC complicated by CPA who received anticancer drug treatment.ResultsA total of 10 patients with LC complicated by CPA received anticancer drug treatment. The median overall survival (OS) was 14.57 months (95% confidence interval [CI]: 5.37–21.67). The cause of death in all patients was LC. Six of the seven patients with LC did not show worsening pulmonary aspergillosis lesions during the anticancer drug treatment. Although two patients discontinued anticancer drug treatment due to pneumonitis, CPA complications did not interfere with the continuation of anticancer drug treatment. In univariate analyses, squamous histology (p = 0.01) and body mass index (<18.5 kg/m2) (p = 0.0008) were significantly associated with poorer OS.ConclusionsThis study demonstrated that the cause of death in LC patients with concomitant CPA who received anticancer drug treatments and effective antifungal treatment was LC progression. Further large‐scale studies are needed to identify the effect of CPA in patients with LC.

show abstract

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy

Morimoto,

Hamashima,

Yamada

et al. 2024

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Chemoimmunotherapy Versus Pembrolizumab as a First-Line Treatment for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression: Focus on the Role of Performance Status

Cited by 1 publication

References 35 publications

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy

Clinical significance of chronic pulmonary aspergillosis in lung cancer patients undergoing anticancer drug therapy

Contact Info

Product

Resources

About